Literature DB >> 7757995

Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables.

S Egawa1, T Uchida, K Suyama, C Wang, M Ohori, S Irie, M Iwamura, K Koshiba.   

Abstract

Sixty-six patients with prostatic adenocarcinoma were screened for somatic instability at 8 microsatellite marker loci on 5 chromosomes. Differences in unrelated microsatellites for tumor and normal DNA were detected in 13 (19.7%) patients. Only extraglandular spread (nodal involvement and distant metastasis) was found to show significant association with somatic instability after controlling for other clinicopathological variables (P < 0.05). Microsatellite instability may possibly occur during the early stages of neoplastic transformation in a subset of prostate cancer rather than as a late event. This may be related to a phenotype with growth advantage. The frequency of this mutator phenotype is much higher in the United States than Japan, reflecting racial differences in the molecular tumorigenesis of this malignancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7757995

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Clinical implications of mismatch repair deficiency in prostate cancer.

Authors:  Ramy Sedhom; Emmanuel S Antonarakis
Journal:  Future Oncol       Date:  2019-06-25       Impact factor: 3.404

Review 2.  The mutation rate and cancer.

Authors:  A L Jackson; L A Loeb
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

3.  High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.

Authors:  Christophe Rosty; Michael D Walsh; Noralane M Lindor; Stephen N Thibodeau; Erin Mundt; Steven Gallinger; Melyssa Aronson; Aaron Pollett; John A Baron; Sally Pearson; Mark Clendenning; Rhiannon J Walters; Belinda N Nagler; William J Crawford; Joanne P Young; Ingrid Winship; Aung Ko Win; John L Hopper; Mark A Jenkins; Daniel D Buchanan
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

4.  MSH2 Loss in Primary Prostate Cancer.

Authors:  Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-08-08       Impact factor: 12.531

5.  Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Authors:  Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

Review 6.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2016-09-27

7.  Patient-derived xenografts and organoids model therapy response in prostate cancer.

Authors:  Sofia Karkampouna; Federico La Manna; Andrej Benjak; Mirjam Kiener; Marta De Menna; Eugenio Zoni; Joël Grosjean; Irena Klima; Andrea Garofoli; Marco Bolis; Arianna Vallerga; Jean-Philippe Theurillat; Maria R De Filippo; Vera Genitsch; David Keller; Tijmen H Booij; Christian U Stirnimann; Kenneth Eng; Andrea Sboner; Charlotte K Y Ng; Salvatore Piscuoglio; Peter C Gray; Martin Spahn; Mark A Rubin; George N Thalmann; Marianna Kruithof-de Julio
Journal:  Nat Commun       Date:  2021-02-18       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.